Achieve Life Sciences Publishes New Study on Cytisinicline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ACHV?
Source: Newsfilter
- Significant Research Findings: Achieve Life Sciences' study published in Nicotine & Tobacco Research reveals that cytisinicline demonstrates a 99% binding affinity at the α4β2 nicotinic receptor, indicating its effectiveness and potential in smoking cessation therapy.
- Tolerability Advantage: The study shows minimal binding (-8% displacement) to the 5-HT3 receptor, which helps explain the low incidence of adverse effects like nausea observed in clinical trials, potentially appealing to more smokers looking to quit.
- Urgent Market Demand: With approximately 25 million adults smoking and 18 million vaping in the U.S., and over half wanting to quit, there is a strong demand for new treatment options, making the development of cytisinicline timely and relevant.
- Regulatory Progress: Achieve Life Sciences has submitted a New Drug Application to the FDA, with a review date set for June 20, 2026, laying the groundwork for cytisinicline's market introduction and potentially transforming the landscape of smoking cessation therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACHV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACHV
Wall Street analysts forecast ACHV stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.670
Low
12.00
Averages
15.50
High
19.00
Current: 2.670
Low
12.00
Averages
15.50
High
19.00
About ACHV
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Achieve Life Sciences Publishes New Study on Cytisinicline
- Significant Research Findings: Achieve Life Sciences' study published in Nicotine & Tobacco Research reveals that cytisinicline demonstrates a 99% binding affinity at the α4β2 nicotinic receptor, indicating its effectiveness and potential in smoking cessation therapy.
- Tolerability Advantage: The study shows minimal binding (-8% displacement) to the 5-HT3 receptor, which helps explain the low incidence of adverse effects like nausea observed in clinical trials, potentially appealing to more smokers looking to quit.
- Urgent Market Demand: With approximately 25 million adults smoking and 18 million vaping in the U.S., and over half wanting to quit, there is a strong demand for new treatment options, making the development of cytisinicline timely and relevant.
- Regulatory Progress: Achieve Life Sciences has submitted a New Drug Application to the FDA, with a review date set for June 20, 2026, laying the groundwork for cytisinicline's market introduction and potentially transforming the landscape of smoking cessation therapies.
See More
Achieve Life Sciences Q4 2025 Earnings Call Insights
- Clinical Transition Progress: Achieve Life Sciences submitted the NDA for cytisinicline in June 2025, marking a shift from clinical to commercial focus, aiming to provide treatment for 25 million smokers and nearly 18 million vapers, demonstrating the company's keen awareness of market demand.
- Regulatory Milestone Achieved: The FDA accepted the NDA for cytisinicline and granted a National Priority Voucher for the vaping indication, providing an accelerated pathway to potential first-in-class approval for vaping cessation, which holds significant market potential.
- Financial Status Update: As of December 31, 2025, the company reported $36.4 million in cash and cash equivalents, with operating expenses of $14.7 million and a net loss of $14.7 million, reflecting ongoing investments in regulatory and commercial preparations despite a cash decrease from the previous quarter.
- Market Readiness and Risk Management: Management has engaged with payers approximately 40 times, emphasizing the differentiated profile of cytisinicline and the unmet market needs, while planning to initiate the ORCA-V2 Phase III trial in vaping cessation in the first half of 2026, showcasing the company's strategic focus on market access and supply chain security.
See More
Iran Allows 'Non-Hostile' Vessels to Transit Strait of Hormuz
- Transit Policy: Iran informed the International Maritime Organization that 'non-hostile' vessels may pass through the Strait of Hormuz if they coordinate with Iranian authorities, aiming to alleviate the shipping crisis caused by ongoing conflicts.
- Shipping Disruption Impact: Since the conflict erupted on February 28, shipping through the Strait has nearly ceased, leaving approximately 3,200 vessels stranded in the Gulf, affecting 20% of global oil shipments and trade for Gulf nations.
- Transit Costs: Some shipping operators have reportedly paid up to $2 million to secure safe passage, reflecting the significant impact of the current situation on shipping costs and operational risks.
- Humanitarian Corridor Exploration: The International Maritime Organization is considering establishing a humanitarian corridor to allow vessels facing fuel or supply shortages to safely exit the region, highlighting the importance of maritime safety amidst escalating tensions.
See More
Achieve Life Sciences Q4 Earnings Miss Expectations
- Earnings Performance: Achieve Life Sciences reported a Q4 GAAP EPS of -$0.28, missing expectations by $0.01, indicating challenges in profitability that could impact investor confidence moving forward.
- Cash Reserves Status: As of December 31, 2025, the company held $36.4 million in cash, cash equivalents, and marketable securities, which, while providing some liquidity, raises concerns about capital efficiency and future funding needs.
- Market Outlook Analysis: The company is viewed as a potential 'best tobacco stock' for 2026, bolstered by endorsement from Hunterbrook Capital, suggesting market anticipation for its upcoming product Cytisinicline, which may lead to stock price volatility.
- Ratings and Analysis: Seeking Alpha's Quant Rating assigns a Strong Buy to Achieve Life Sciences, reflecting analysts' optimism about the company's growth potential despite its current financial performance.
See More
ACHIEVE LIFE SCIENCES INC REPORTS Q4 NET LOSS OF $14.7 MILLION, FY2025 NET LOSS TOTALS $54.7 MILLION
Q4 Financial Performance: The company reported a net loss of $14.7 million for the fourth quarter.
FY 2025 Projections: For the fiscal year 2025, the projected net loss is $54.7 million.
See More
Achieve Life Sciences Set to Announce Q4 Earnings on March 24
- Earnings Announcement: Achieve Life Sciences is set to release its Q4 earnings on March 24 after market close, with a consensus EPS estimate of -$0.28, reflecting a 22.2% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: While the revenue estimate stands at $0, analysts remain optimistic about the company's growth potential, particularly regarding the development of its core product, Cytisinicline, which could open new revenue streams.
- Market Reaction: The stock of Achieve Life Sciences has recently surged following an endorsement from Hunterbrook Capital, reflecting investor confidence in the company's future prospects, which may lead to further stock price volatility post-earnings announcement.
- Investment Rating: Seeking Alpha's Quant Rating has assigned a
See More
Achieve Life Sciences Publishes New Study on Cytisinicline
- Significant Research Findings: Achieve Life Sciences' study published in Nicotine & Tobacco Research reveals that cytisinicline demonstrates a 99% binding affinity at the α4β2 nicotinic receptor, indicating its effectiveness and potential in smoking cessation therapy.
- Tolerability Advantage: The study shows minimal binding (-8% displacement) to the 5-HT3 receptor, which helps explain the low incidence of adverse effects like nausea observed in clinical trials, potentially appealing to more smokers looking to quit.
- Urgent Market Demand: With approximately 25 million adults smoking and 18 million vaping in the U.S., and over half wanting to quit, there is a strong demand for new treatment options, making the development of cytisinicline timely and relevant.
- Regulatory Progress: Achieve Life Sciences has submitted a New Drug Application to the FDA, with a review date set for June 20, 2026, laying the groundwork for cytisinicline's market introduction and potentially transforming the landscape of smoking cessation therapies.
See More
Achieve Life Sciences Q4 2025 Earnings Call Insights
- Clinical Transition Progress: Achieve Life Sciences submitted the NDA for cytisinicline in June 2025, marking a shift from clinical to commercial focus, aiming to provide treatment for 25 million smokers and nearly 18 million vapers, demonstrating the company's keen awareness of market demand.
- Regulatory Milestone Achieved: The FDA accepted the NDA for cytisinicline and granted a National Priority Voucher for the vaping indication, providing an accelerated pathway to potential first-in-class approval for vaping cessation, which holds significant market potential.
- Financial Status Update: As of December 31, 2025, the company reported $36.4 million in cash and cash equivalents, with operating expenses of $14.7 million and a net loss of $14.7 million, reflecting ongoing investments in regulatory and commercial preparations despite a cash decrease from the previous quarter.
- Market Readiness and Risk Management: Management has engaged with payers approximately 40 times, emphasizing the differentiated profile of cytisinicline and the unmet market needs, while planning to initiate the ORCA-V2 Phase III trial in vaping cessation in the first half of 2026, showcasing the company's strategic focus on market access and supply chain security.
See More
Iran Allows 'Non-Hostile' Vessels to Transit Strait of Hormuz
- Transit Policy: Iran informed the International Maritime Organization that 'non-hostile' vessels may pass through the Strait of Hormuz if they coordinate with Iranian authorities, aiming to alleviate the shipping crisis caused by ongoing conflicts.
- Shipping Disruption Impact: Since the conflict erupted on February 28, shipping through the Strait has nearly ceased, leaving approximately 3,200 vessels stranded in the Gulf, affecting 20% of global oil shipments and trade for Gulf nations.
- Transit Costs: Some shipping operators have reportedly paid up to $2 million to secure safe passage, reflecting the significant impact of the current situation on shipping costs and operational risks.
- Humanitarian Corridor Exploration: The International Maritime Organization is considering establishing a humanitarian corridor to allow vessels facing fuel or supply shortages to safely exit the region, highlighting the importance of maritime safety amidst escalating tensions.
See More
Achieve Life Sciences Q4 Earnings Miss Expectations
- Earnings Performance: Achieve Life Sciences reported a Q4 GAAP EPS of -$0.28, missing expectations by $0.01, indicating challenges in profitability that could impact investor confidence moving forward.
- Cash Reserves Status: As of December 31, 2025, the company held $36.4 million in cash, cash equivalents, and marketable securities, which, while providing some liquidity, raises concerns about capital efficiency and future funding needs.
- Market Outlook Analysis: The company is viewed as a potential 'best tobacco stock' for 2026, bolstered by endorsement from Hunterbrook Capital, suggesting market anticipation for its upcoming product Cytisinicline, which may lead to stock price volatility.
- Ratings and Analysis: Seeking Alpha's Quant Rating assigns a Strong Buy to Achieve Life Sciences, reflecting analysts' optimism about the company's growth potential despite its current financial performance.
See More
ACHIEVE LIFE SCIENCES INC REPORTS Q4 NET LOSS OF $14.7 MILLION, FY2025 NET LOSS TOTALS $54.7 MILLION
Q4 Financial Performance: The company reported a net loss of $14.7 million for the fourth quarter.
FY 2025 Projections: For the fiscal year 2025, the projected net loss is $54.7 million.
See More
Achieve Life Sciences Set to Announce Q4 Earnings on March 24
- Earnings Announcement: Achieve Life Sciences is set to release its Q4 earnings on March 24 after market close, with a consensus EPS estimate of -$0.28, reflecting a 22.2% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: While the revenue estimate stands at $0, analysts remain optimistic about the company's growth potential, particularly regarding the development of its core product, Cytisinicline, which could open new revenue streams.
- Market Reaction: The stock of Achieve Life Sciences has recently surged following an endorsement from Hunterbrook Capital, reflecting investor confidence in the company's future prospects, which may lead to further stock price volatility post-earnings announcement.
- Investment Rating: Seeking Alpha's Quant Rating has assigned a
See More
